Statement of Changes in Beneficial Ownership (4)
March 02 2021 - 5:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Arcudi III Louis J |
2. Issuer Name and Ticker or Trading Symbol
Millendo Therapeutics, Inc.
[
MLND
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and CEO |
(Last)
(First)
(Middle)
C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/26/2021 |
(Street)
ANN ARBOR, MI 48104
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $2.06 | 2/26/2021 | | A | | 400000 | | (1) | 2/25/2031 | Common Stock | 400000.0 | $0 | 400000 | D | |
Explanation of Responses: |
(1) | 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Arcudi III Louis J C/O MILLENDO THERAPEUTICS, INC. 110 MILLER AVENUE, SUITE 100 ANN ARBOR, MI 48104 | X |
| President and CEO |
|
Signatures
|
/s/ Jason Minio, Attorney-in-Fact | | 3/2/2021 |
**Signature of Reporting Person | Date |
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Millendo Therapeutics (NASDAQ:MLND)
Historical Stock Chart
From Sep 2023 to Sep 2024